Search results
Showing 1 to 15 of 26 results for semaglutide
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
In development Reference number: GID-TA11477 Expected publication date: TBC
In development Reference number: GID-TA11544 Expected publication date: 14 May 2026
Awaiting development Reference number: GID-TA10438 Expected publication date: TBC
NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA910
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [TSID11905] [ID6529]
Awaiting development Reference number: GID-TA11414 Expected publication date: TBC
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....
People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.